Geriatrik Testis Penis Adrenal Kanserlerine Yaklaşım
Özet
Geriatride testis kanserleri nadiren görülür ve genellikle düşük dereceli olgularla ilişkilidir. Testis tümörleri en sık genç erişkinlerde ortaya çıksa da, yaşlı bireylerde de tanımlanabilir. Semptomlar arasında testis kitlesi ve ağrısız şişlik bulunur. Tanı genellikle ultrasonografi ve tümör belirteçleriyle konur. Tedavi seçenekleri arasında cerrahi, kemoterapi ve radyasyon tedavisi yer alır. Yaşlı hastalarda tedavi yaklaşımları, komorbiditeler ve yaşam kalitesi göz önünde bulundurularak uyarlanır. Penis kanserleri ise nadiren görülen malignitelerdir ve genellikle glans ve prepisyum bölgelerinde ortaya çıkar. Risk faktörleri arasında insan papilloma virüsü (HPV) enfeksiyonu, kötü hijyen ve sigara kullanımı bulunur. Semptomlar arasında nodül, ülser ve başarılı olmayan yara iyileşmesidir. Tanı, klinik muayene ve biyopsiyle konur. Tedavi, tümörün evresine göre cerrahi, radyoterapi ve kemoterapiyi içerebilir. Yaşlılarda, tedavi kararları hastanın genel durumu ve yaşam kalitesi doğrultusunda alınır. Adrenal tümörler, benign veya malign olabilirler. Semptomlar çoğu zaman görülmez veya non-spesifik olup, hormon fazlalığı ya da kitle varlığıyla kendini gösterebilir. Tanı, görüntüleme yöntemleri ve hormon testleriyle konur. Cerrahi ve tıbbi tedavi seçenekleri, tümör tipi ve hastanın genel durumu dikkate alınarak belirlenir. Geriatrik hastalarda, tedavi yaklaşımı, hastanın komorbiditeleri ve yaşam kalitesi göz önünde bulundurularak uyarlanır.
Referanslar
Ng L, Libertino JM. Adrenocortical carcinoma: Diagnosis, evaluation and treatment. Journal of Urology 2003;169(1):5-11
Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: Analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996;119(2):161-710
Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. The Journal of Clinical Endocrinology & Metabolism. 2002;87(12):5367-5384
Kjellman M, Roshani L, Teh BT, et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. The Journal of Clinical Endocrinology & Metabolism. 1999;84(2):730-735
Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR. American journal of roentgenology. 2008;190(5):1163–1168
Russell RP, Masi AT, Richter ED. Adrenal cortical adenomas and hypertension. A clinical pathologic analysis of 690 cases with matched controls and a review of the literature. Medicine (Baltimore). 1972;51(3):211–225
Ayala-Ramirez, M., Jasim, S., Feng, L., et al. (2013). Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center. Europenan Journal of Endocrinology. 169, 891–899. doi:10.1530/EJE-13-0519
Schteingart DE, Giordano TJ, Benitez RS, et al. Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome. The Journal of Clinical Endocrinology & Metabolism. 2001; 86:3968
Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best practice & research. Clinical endocrinology & metabolism. 2009; 23:273
Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology. 2016; 175:G1
Debono M, Bradburn M, Bull M, et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. The Journal of Clinical Endocrinology & Metabolism 2014; 99:4462
Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2008; 93:3266
Gaujoux S, Grabar S, Fassnacht M, et al. β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clinical Cancer Research. 2011; 17:328
Libè R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clinical Cancer Research. 2007; 13:844
Zheng S, Cherniack AD, Dewal N, et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 2016; 29:723
U Waszut, P Szyszka, D Dworakowska. Understanding mitotane mode of action. Journal of Physiology and Pharmacology. 2017 Feb;68(1):13-26
Phan AT, Grogan RH, Rohrer E, et al. Adrenal Cortical Carcinoma. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), Springer, New York 2017. p.911
Kiseljak-Vassiliades K,Bancos I, Hamrahian A, et al. American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach. Endocrine Practice. 2020 Nov;26(11):1366-1383
Else, T., Kim, A. C., Sabolch, A., et al. (2014). Adrenocortical carcinoma. Endocrine Reviews. 35, 282–326. doi:10.1210/er.2013-1029
He S, Huang X, Zhao P, et al. The prognosis difference between elderly and younger patients with adrenocortical carcinoma. Frontiers in Genetics. 2023 Jan 4; 13:1029155. doi: 10.3389/fgene.2022.1029155. PMID: 36685908; PMCID: PMC9845245
Huisman, M. G., Kok, M., de Bock, G. H., et al. (2017). Delivering tailored surgery to older cancer patients: Preoperative geriatric assessment domains and screening tools- a systematic review of systematic reviews. European Journal of Surgical Oncology. 43, 1–14. doi: 10.1016/j.ejso.2016.06.003
Kemeny, M. M., Busch-Devereaux, E., Merriam, L. T., et al. (2000). Cancer surgery in the elderly. Hematology/oncology clinics of North America.14, 169–192. doi:10.1016/s0889-8588(05)70283-5
Luton, J. P., Cerdas, S., Billaud, L., et al. (1990). Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. The New England Journal Of Medicine. 322, 1195–1201. doi:10.1056/NEJM199004263221705
Sinclair, T. J., Gillis, A., Alobuia, W. M., et al. (2020). Surgery for adrenocortical carcinoma: When and how? Best practice & research. Clinical endocrinology & metabolism. 34, 101408. doi: 10.1016/j.beem.2020.101408
Deschner, B. W., Stiles, Z. E., DeLozier, O. M., et al. (2020). Critical analysis of lymph node examination in patients undergoing curative-intent resection for adrenocortical carcinoma. Journal of Surgical Oncology. 122, 1152–1162. doi:10.1002/jso.26138.
Polat, B., Fassnacht, M., Pfreundner, L., et al. (2009). Radiotherapy in adrenocortical carcinoma. Cancer. 115, 2816–2823. doi:10.1002/cncr.24331
Wajchenberg, B. L., Albergaria Pereira, M. A., Medonca, B. B., et al. (2000). Adrenocortical carcinoma: Clinical and laboratory observations. Cancer. 88, 711–736.doi:10.1002/(sici)1097-0142(20000215)88:4
Viani, G. A., and Viana, B. S. (2019). Adjuvant radiotherapy after surgical resection for adrenocortical carcinoma: A systematic review of observational studies and meta-analysis. Journal of Cancer Research and Therapeutics. 15, S20-S26–s26. doi:10.4103/jcrt.JCRT_996_15
Kimpel, O., Bedrose, S., Megerle, F., et al. (2021). Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: A cohort study. British Journal of Cancer. 125, 1233–1238. doi:10.1038/s41416-021-01513-8
